000180668 001__ 180668
000180668 005__ 20240229145627.0
000180668 0247_ $$2doi$$a10.1016/j.lanepe.2022.100458
000180668 0247_ $$2pmid$$apmid:35832063
000180668 0247_ $$2pmc$$apmc:PMC9272368
000180668 0247_ $$2altmetric$$aaltmetric:130783127
000180668 037__ $$aDKFZ-2022-01468
000180668 041__ $$aEnglish
000180668 082__ $$a610
000180668 1001_ $$0P:(DE-HGF)0$$aCardoso, Rafael$$b0$$eFirst author
000180668 245__ $$aOverall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: A population-based study in 9 countries.
000180668 260__ $$a[Amsterdam]$$bElsevier$$c2022
000180668 3367_ $$2DRIVER$$aarticle
000180668 3367_ $$2DataCite$$aOutput Types/Journal article
000180668 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1657887714_25626
000180668 3367_ $$2BibTeX$$aARTICLE
000180668 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180668 3367_ $$00$$2EndNote$$aJournal Article
000180668 500__ $$a#EA:C120#LA:C120#LA:C070#
000180668 520__ $$aAn increasing proportion of colorectal cancers (CRCs) are detected through screening due to the availability of organised population-based programmes. We aimed to analyse survival probabilities of patients with screen-detected CRC in European countries.Data from CRC patients were obtained from 16 population-based cancer registries in nine European countries. We included patients with cancer diagnosed from the year organised CRC screening programmes were introduced until the most recent year with available data at the time of analysis, whose ages at diagnosis fell into the age groups targeted by screening. Patients were followed up with regards to vital status until 2016-2020 across the various countries. Overall and CRC-specific survival were analysed by mode of detection and stage at diagnosis for all countries combined and for each country separately using the Kaplan-Meier method.We included data from 228 134 patients, of whom 134 597 (aged 60-69 years at diagnosis targeted by screening in all countries) were considered in analyses for all countries combined. 22·3% (38 080/134 597) of patients had cancer detected through screening. Most screen-detected cancers were found at stages I-II (65·6% [12 772/19 469 included in stage-specific analyses]), while the majority of non-screen-detected cancers were found at stages III-IV (56·4% [31 882/56 543 included in stage-specific analyses]). Five-year overall and CRC-specific survival rates for patients with screen-detected cancer were 83·4% (95% CI 82·9-83·9) and 89·2% (88·8-89·7), respectively; for patients with non-screen-detected cancer, they were much lower (57·5% [57·2-57·8] and 65·7% [65·4-66·1], respectively). The favourable survival of patients with screen-detected cancer was also seen within each stage - five-year overall survival rates for patients with screen-detected stage I, II, III, and IV cancers were 92.4% (95% CI 91·6-93·1), 87·9% (86·6-89·1), 80·7% (79·3-82·0), and 32·3 (29·4-35·2), respectively. These patterns were also consistently seen for each individual country.Patients with cancer diagnosed at screening have a very favourable prognosis. In the rare case of detection of advanced stage cancer, survival probabilities are still much higher than those commonly reported for all patients regardless of mode of detection. Although these results cannot be taken to quantify screening effects, they provide useful and encouraging information for patients with screen-detected CRC and their physicians.This study was supported in part by grants from the German Federal Ministry of Education and Research and the German Cancer Aid.
000180668 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000180668 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180668 650_7 $$2Other$$aColorectal cancer
000180668 650_7 $$2Other$$aEurope
000180668 650_7 $$2Other$$aScreening
000180668 650_7 $$2Other$$aSurvival
000180668 7001_ $$0P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919$$aGuo, Feng$$b1$$udkfz
000180668 7001_ $$0P:(DE-HGF)0$$aHeisser, Thomas$$b2
000180668 7001_ $$aDe Schutter, Harlinde$$b3
000180668 7001_ $$aVan Damme, Nancy$$b4
000180668 7001_ $$aNilbert, Mef Christina$$b5
000180668 7001_ $$aChristensen, Jane$$b6
000180668 7001_ $$aBouvier, Anne-Marie$$b7
000180668 7001_ $$aBouvier, Véronique$$b8
000180668 7001_ $$aLaunoy, Guy$$b9
000180668 7001_ $$aWoronoff, Anne-Sophie$$b10
000180668 7001_ $$aCariou, Mélanie$$b11
000180668 7001_ $$aRobaszkiewicz, Michel$$b12
000180668 7001_ $$aDelafosse, Patricia$$b13
000180668 7001_ $$aPoncet, Florence$$b14
000180668 7001_ $$aWalsh, Paul M$$b15
000180668 7001_ $$aSenore, Carlo$$b16
000180668 7001_ $$aRosso, Stefano$$b17
000180668 7001_ $$aLemmens, Valery E P P$$b18
000180668 7001_ $$aElferink, Marloes A G$$b19
000180668 7001_ $$aTomšič, Sonja$$b20
000180668 7001_ $$aŽagar, Tina$$b21
000180668 7001_ $$aMarques, Arantza Lopez de Munain$$b22
000180668 7001_ $$aMarcos-Gragera, Rafael$$b23
000180668 7001_ $$aPuigdemont, Montse$$b24
000180668 7001_ $$aGalceran, Jaume$$b25
000180668 7001_ $$aCarulla, Marià$$b26
000180668 7001_ $$aSánchez-Gil, Antonia$$b27
000180668 7001_ $$aChirlaque, María-Dolores$$b28
000180668 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b29$$udkfz
000180668 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b30$$eLast author$$udkfz
000180668 773__ $$0PERI:(DE-600)3055963-7$$a10.1016/j.lanepe.2022.100458$$gVol. 21, p. 100458 -$$p100458$$tThe lancet / Regional health. Europe$$v21$$x2666-7762$$y2022
000180668 909CO $$ooai:inrepo02.dkfz.de:180668$$pVDB
000180668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b29$$kDKFZ
000180668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000180668 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000180668 9141_ $$y2022
000180668 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000180668 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000180668 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-12-02T13:40:13Z
000180668 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-12-02T13:40:13Z
000180668 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-12-02T13:40:13Z
000180668 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000180668 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2022-11-25
000180668 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000180668 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000180668 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000180668 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000180668 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000180668 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000180668 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000180668 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000180668 980__ $$ajournal
000180668 980__ $$aVDB
000180668 980__ $$aI:(DE-He78)C120-20160331
000180668 980__ $$aI:(DE-He78)C070-20160331
000180668 980__ $$aI:(DE-He78)HD01-20160331
000180668 980__ $$aUNRESTRICTED